{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:39:04Z","timestamp":1786984744367,"version":"build-2736575974"},"reference-count":38,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008688","name":"Cinvestav","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008688","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Medical Research"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.arcmed.2026.103388","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T20:21:51Z","timestamp":1770063711000},"page":"103388","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Introducing an In Vivo Protocol to Evaluate Skin Penetration of Topical Drugs: Proof-of-Concept with Naproxen in Humans"],"prefix":"10.1016","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3036-1657","authenticated-orcid":false,"given":"Mariannela C.","family":"Ruiz-Ruiz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6086-0306","authenticated-orcid":false,"given":"Mar\u00eda de Lourdes","family":"Gonz\u00e1lez-Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"V\u00e1zquez-Rom\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Miguel","family":"Jim\u00e9nez-Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8502-7098","authenticated-orcid":false,"given":"Hector A.","family":"Cabrera-Fuentes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilberto","family":"Casta\u00f1eda-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arcmed.2026.103388_bib0001","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/acr.24131","article-title":"2019 American College of Rheumatology\/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee","volume":"72","author":"Kolasinski","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.arcmed.2026.103388_bib0002","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41584-020-00523-9","article-title":"Non-surgical management of knee osteoarthritis: comparison of ESCEO and OARSI 2019 guidelines","volume":"17","author":"Arden","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.arcmed.2026.103388_bib0003","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.3390\/jcm12041544","article-title":"Multidisciplinary Guidelines for the Rational Use of Topical Non-Steroidal Anti-Inflammatory Drugs for Musculoskeletal Pain (2022)","volume":"12","author":"Shi","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.arcmed.2026.103388_bib0004","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s10787-999-0028-6","article-title":"Percutaneous absorption of topically applied NSAIDS and other compounds: Role of solute properties, skin physiology and delivery systems","volume":"7","author":"Roberts","year":"1999","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.arcmed.2026.103388_bib0005","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1080\/03007995.2017.1352497","article-title":"Skin penetration and tissue permeation after topical administration of diclofenac","volume":"33","author":"Hagen","year":"2017","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.arcmed.2026.103388_bib0006","article-title":"Topical analgesics for acute and chronic pain in adults - an overview of Cochrane Reviews","volume":"5","author":"Derry","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.arcmed.2026.103388_bib0007","unstructured":"U.S. Food and Drug Administration. In Vitro Permeation Test Studies for Topical Drug Products Submitted in ANDAs: Draft Guidance for Industry. https:\/\/www.fda.gov\/media\/162475\/download. (Accessed June 25, 2025)."},{"key":"10.1016\/j.arcmed.2026.103388_bib0008","unstructured":"U.S. Food and Drug Administration. In Vitro Release Test Studies for Topical Drug Products Submitted in ANDAs: Draft Guidance for Industry. https:\/\/www.fda.gov\/media\/162476\/download. (Accessed June 25, 2025)."},{"key":"10.1016\/j.arcmed.2026.103388_bib0009","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1185\/030079907X242584","article-title":"Persistence of NSAIDs at effect sites and rapid disappearance from side-effect compartments contributes to tolerability","volume":"23","author":"Brune","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.arcmed.2026.103388_bib0010","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ejpb.2004.09.015","article-title":"IV\u2013IVC for topically applied preparations\u2013a critical evaluation","volume":"60","author":"Shah","year":"2005","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.arcmed.2026.103388_bib0011","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/s11095-013-1169-2","article-title":"In vitro\u2013In vivo Correlation in Skin Permeation","volume":"31","author":"Mohammed","year":"2014","journal-title":"Pharm Res"},{"key":"10.1016\/j.arcmed.2026.103388_bib0012","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11095-007-9429-7","article-title":"In vivo methods for the assessment of topical drug bioavailability","volume":"25","author":"Herkenne","year":"2008","journal-title":"Pharm Res"},{"key":"10.1016\/j.arcmed.2026.103388_bib0013","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.addr.2012.04.009","article-title":"Mathematical and pharmacokinetic modelling of epidermal and dermal transport processes","volume":"65","author":"Anissimov","year":"2013","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.arcmed.2026.103388_bib0014","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/ddr.430360404","article-title":"Procedure for the evaluation of the bioavailability of topical formulations in vivo as the rate and extent to which the active drug product is transferred from the vehicle to the skin","volume":"36","author":"Verg\u00e9s","year":"1995","journal-title":"Drug Dev Res"},{"key":"10.1016\/j.arcmed.2026.103388_bib0015","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0378-5173(89)90306-2","article-title":"A simple equation for the description of solute release. III. Coupling of diffusion and relaxation","volume":"57","author":"Peppas","year":"1989","journal-title":"Int J Pharm"},{"key":"10.1016\/j.arcmed.2026.103388_bib0016","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1159\/000497225","article-title":"Permeation Mechanism of Caffeine and Naproxen through in vitro Human Epidermis: Effect of Vehicles and Penetration Enhancers","volume":"32","author":"Abd","year":"2019","journal-title":"Skin Pharmacol Physiol"},{"key":"10.1016\/j.arcmed.2026.103388_bib0017","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0026-2862(70)90004-X","article-title":"Comparative analysis of the protein content of local subcutaneous tissue fluid and plasma","volume":"2","author":"Haljam\u00e4e","year":"1970","journal-title":"Microvasc Res"},{"key":"10.1016\/j.arcmed.2026.103388_bib0018","first-page":"5","article-title":"Age-related percutaneous penetration part 2: effect of age on dermatopharmacokinetics and overview of transdermal products","volume":"17","author":"Konda","year":"2012","journal-title":"Skin Therapy Lett"},{"key":"10.1016\/j.arcmed.2026.103388_bib0019","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/s12905-023-02395-z","article-title":"The menstrual cycle regularity and skin: irregular menstrual cycle affects skin physiological properties and skin bacterial microbiome in urban Chinese women","volume":"23","author":"Ma","year":"2023","journal-title":"BMC Womens Health"},{"key":"10.1016\/j.arcmed.2026.103388_bib0020","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1093\/ajhp\/zxac058","article-title":"Implications of obesity for drug administration and absorption from subcutaneous and intramuscular injections: A primer","volume":"79","author":"Erstad","year":"2022","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.arcmed.2026.103388_bib0021","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/15569527.2020.1787434","article-title":"Effects of anatomical location on in vivo percutaneous penetration in man","volume":"39","author":"Bormann","year":"2020","journal-title":"Cutan Ocul Toxicol"},{"key":"10.1016\/j.arcmed.2026.103388_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121469","article-title":"Skin pharmacokinetics of diclofenac and co-delivered functional excipients","volume":"614","author":"Tabosa","year":"2022","journal-title":"Int J Pharm"},{"key":"10.1016\/j.arcmed.2026.103388_bib0023","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s004200050228","article-title":"Time-resolved cutaneous absorption and permeation rates of methanol in human volunteers","volume":"70","author":"Batterman","year":"1997","journal-title":"Int Arch Occup Environ Health"},{"key":"10.1016\/j.arcmed.2026.103388_bib0024","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1080\/00319104.2016.1140763","article-title":"Solubility and preferential solvation of some non-steroidal anti-inflammatory drugs in methanol + water mixtures at 298.15 K","volume":"54","author":"Jim\u00e9nez","year":"2016","journal-title":"Phys Chem Liquids"},{"key":"10.1016\/j.arcmed.2026.103388_bib0025","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/BF01060893","article-title":"Some Suggestions for Measuring Predictive Performance","volume":"9","author":"Sheiner","year":"1989","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1016\/j.arcmed.2026.103388_bib0026","doi-asserted-by":"crossref","DOI":"10.1111\/petr.13595","article-title":"Limited sampling strategy to predict the area under the curve of tacrolimus in Mexican renal transplant pediatric patients receiving Prograf\u00ae or non-innovator formulations","volume":"23","author":"Medina-Aymerich","year":"2019","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.arcmed.2026.103388_bib0027","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2253-3-4","article-title":"Single-dose oral naproxen for acute postoperative pain: a quantitative systematic review","volume":"3","author":"Mason","year":"2003","journal-title":"BMC Anesthesiol"},{"key":"10.1016\/j.arcmed.2026.103388_bib0028","series-title":"Topical Drug Bioavailability, Bioequivalence, and Penetration","author":"Shah","year":"2014"},{"key":"10.1016\/j.arcmed.2026.103388_bib0029","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0022-3565(25)38459-4","article-title":"Skin permeability and local tissue concentrations of nonsteroidal anti-inflammatory drugs after topical application","volume":"268","author":"Singh","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.arcmed.2026.103388_bib0030","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/BF00609198","article-title":"Transcutaneous Absorption of Naproxen Gel","volume":"36","author":"Van Den Ouweland","year":"1989","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.arcmed.2026.103388_bib0031","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/sj.jid.5700642","article-title":"Dermatopharmacokinetic Prediction of Topical Drug Bioavailability In vivo","volume":"127","author":"Herkenne","year":"2007","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.arcmed.2026.103388_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2024.114394","article-title":"Mechanisms of penetration and diffusion of drugs and cosmetic actives across the human Stratum corneum","volume":"202","author":"Neubert","year":"2024","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.arcmed.2026.103388_bib0033","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3390\/pharmaceutics7040438","article-title":"Transdermal drug delivery: Innovative pharmaceutical developments based on disruption of the barrier properties of the stratum corneum","volume":"7","author":"Alkilani","year":"2015","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.arcmed.2026.103388_bib0034","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/15360288.2017.1301616","article-title":"Oral Versus Topical Diclofenac Sodium in the Treatment of Osteoarthritis","volume":"31","author":"Tieppo Francio","year":"2017","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"10.1016\/j.arcmed.2026.103388_bib0035","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/(SICI)1099-081X(199710)18:7<623::AID-BDD46>3.0.CO;2-V","article-title":"Pharmacokinetic and local tissue disposition studies of naproxen-following topical and systemic administration in dogs and rats","volume":"18","author":"Suh","year":"1997","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.arcmed.2026.103388_bib0036","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0009-9236(99)70128-1","article-title":"Application of microdialysis for the determination of muscle and subcutaneous tissue concentrations after oral and topical ibuprofen administration","volume":"65","author":"Tegeder","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.arcmed.2026.103388_bib0037","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S0022-3565(24)29528-8","article-title":"Pharmacokinetic\/pharmacodynamic modeling of antipyretic and anti-inflammatory effects of naproxen in the rat","volume":"297","author":"Josa","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.arcmed.2026.103388_bib0038","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3810\/psm.2010.06.1784","article-title":"Update on the use of topical NSAIDs for the treatment of soft tissue and musculoskeletal pain: a review of recent data and current treatment options","volume":"38","author":"Brewer","year":"2010","journal-title":"Phys Sportsmed"}],"container-title":["Archives of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440926000111?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440926000111?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T13:21:21Z","timestamp":1780665681000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0188440926000111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0188440926000111"],"URL":"https:\/\/doi.org\/10.1016\/j.arcmed.2026.103388","relation":{},"ISSN":["0188-4409"],"issn-type":[{"value":"0188-4409","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Introducing an In Vivo Protocol to Evaluate Skin Penetration of Topical Drugs: Proof-of-Concept with Naproxen in Humans","name":"articletitle","label":"Article Title"},{"value":"Archives of Medical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arcmed.2026.103388","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of Instituto Mexicano del Seguro Social (IMSS).","name":"copyright","label":"Copyright"}],"article-number":"103388"}}